Ofatumumab sBLA Is Accepted for Treatment of Relapsing Multiple Sclerosis

The novel B-cell therapy has been assigned a PDUFA date of June 2020.

Source link

Related posts

Serum glutamine and hospital-acquired infections after aneurysmal subarachnoid hemorrhage


clinical neurology; +227 new citations


Circulating ceramide ratios may be useful predictors of future dementia risk


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy